Inflammation Mediates the Causal Effect of MMP9 on Benign Prostatic Hyperplasia: A Mendelian Randomization Study
Andrologia · 2026-01 · 2026 (1)
DOI: 10.1155/and/3541569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Andrologia, online erschienen am 30.05.2026. Verfasst von Yu Cai und 4 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Matrix metalloproteinases (MMPs) are implicated in tissue remodeling and inflammation, yet their causal roles in prostate diseases remain unclear. This study employed two‐sample Mendelian randomization (MR) to investigate genetic evidence for causal relationships between MMPs and prostate diseases. Materials and Methods First, univariable MR (UVMR) was used to assess the causal effects of ten genetically predicted MMPs on four prostate diseases. Genetic instruments for MMPs were derived from genome‐wide association study (GWAS) catalog data, while prostate disease outcomes were sourced from FinnGen R12. Inverse variance weighted (IVW), MR‐Egger, weighted median, and weighted mode methods were applied. For robust associations, multivariable MR (MVMR) was performed to investigate the mediating effects of key inflammatory markers. Sensitivity analyses included Cochran’s Q , MR‐PRESSO, and leave‐one‐out tests.
Results
In the UVMR analysis, genetically predicted higher levels of MMP9 were causally associated with a modest, but statistically significant, increased risk of benign prostatic hyperplasia (BPH; odds ratio [OR] = 1.052, 95% confidence interval [CI]: 1.019–1.085, p = 0.0015). This was the only association to survive false discovery rate (FDR) correction ( q < 0.10). Nominal associations were observed for MMP10 with prostatitis and MMP12 with malignant prostate neoplasm. Critically, in the MVMR analysis, the causal effect of MMP9 on BPH was substantially attenuated and became nonsignificant after adjusting for genetically predicted levels of C‐reactive protein (OR = 1.046, 95% CI: 0.983–1.114, p = 0.152) and other inflammatory mediators.
Conclusion
This study provides robust genetic evidence supporting a causal relationship between elevated MMP9 levels and the risk of BPH, which appears to be largely mediated by inflammatory pathways.
Zitieren
APA
Cai, Y., Li, X., Yang, C., Zhang, J., & Zhong, Y. (2026). Inflammation Mediates the Causal Effect of MMP9 on Benign Prostatic Hyperplasia: A Mendelian Randomization Study. Andrologia, 2026(1). https://doi.org/10.1155/and/3541569
Vancouver
Cai Y, Li X, Yang C, Zhang J, Zhong Y. Inflammation Mediates the Causal Effect of MMP9 on Benign Prostatic Hyperplasia: A Mendelian Randomization Study. Andrologia. 2026;2026(1). doi:10.1155/and/3541569
BibTeX
@article{Cai2026,
author = {Cai, Yu and Li, Xiongjuan and Yang, Chunyan and Zhang, Jing and Zhong, Yuting},
title = {Inflammation Mediates the Causal Effect of MMP9 on Benign Prostatic Hyperplasia: A Mendelian Randomization Study},
journal = {Andrologia},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/and/3541569}
}
EUVIMED